首页 > 最新文献

Current Oncology Reports最新文献

英文 中文
Statins for the Primary Prevention of Anthracycline Cardiotoxicity: A Comprehensive Review. 他汀类药物用于蒽环类药物心脏毒性的一级预防:全面回顾。
IF 4.7 2区 医学 Q1 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-07-13 DOI: 10.1007/s11912-024-01579-6
Varun Bhasin, Azin Vakilpour, Marielle Scherrer-Crosbie

Purpose of review: The aim of this review is two-fold: (1) To examine the mechanisms by which statins may protect from anthracycline-induced cardiotoxicity and (2) To provide a comprehensive overview of the existing clinical literature investigating the role of statins for the primary prevention of anthracycline-induced cardiotoxicity.

Recent findings: The underlying cardioprotective mechanisms associated with statins have not been fully elucidated. Key mechanisms related to the inhibition of Ras homologous (Rho) GTPases have been proposed. Data from observational studies has supported the beneficial role of statins for the primary prevention of anthracycline-induced cardiotoxicity. Recently, several randomized controlled trials investigating the role of statins for the primary prevention of anthracycline-induced cardiotoxicity have produced contrasting results. Statins have been associated with a lower risk of cardiac dysfunction in cancer patients receiving anthracyclines. Further investigation with larger randomized control trials and longer follow-up periods are needed to better evaluate the long-term role of statin therapy and identify the subgroups who benefit most from statin therapy.

综述目的:本综述有两个目的:(1) 研究他汀类药物可预防蒽环类药物诱发的心脏毒性的机制;(2) 全面概述现有的临床文献,研究他汀类药物在初级预防蒽环类药物诱发的心脏毒性中的作用:他汀类药物的心脏保护机制尚未完全阐明。有人提出了与抑制 Ras 同源(Rho)GTP 酶有关的关键机制。来自观察性研究的数据支持他汀类药物在初级预防蒽环类药物引起的心脏毒性方面的有益作用。最近,几项随机对照试验对他汀类药物在初级预防蒽环类诱导的心脏毒性方面的作用进行了调查,结果却截然不同。他汀类药物可降低接受蒽环类药物治疗的癌症患者出现心脏功能障碍的风险。为了更好地评估他汀类药物治疗的长期作用,并确定从他汀类药物治疗中获益最多的亚组,还需要通过更大规模的随机对照试验和更长的随访期进行进一步调查。
{"title":"Statins for the Primary Prevention of Anthracycline Cardiotoxicity: A Comprehensive Review.","authors":"Varun Bhasin, Azin Vakilpour, Marielle Scherrer-Crosbie","doi":"10.1007/s11912-024-01579-6","DOIUrl":"10.1007/s11912-024-01579-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>The aim of this review is two-fold: (1) To examine the mechanisms by which statins may protect from anthracycline-induced cardiotoxicity and (2) To provide a comprehensive overview of the existing clinical literature investigating the role of statins for the primary prevention of anthracycline-induced cardiotoxicity.</p><p><strong>Recent findings: </strong>The underlying cardioprotective mechanisms associated with statins have not been fully elucidated. Key mechanisms related to the inhibition of Ras homologous (Rho) GTPases have been proposed. Data from observational studies has supported the beneficial role of statins for the primary prevention of anthracycline-induced cardiotoxicity. Recently, several randomized controlled trials investigating the role of statins for the primary prevention of anthracycline-induced cardiotoxicity have produced contrasting results. Statins have been associated with a lower risk of cardiac dysfunction in cancer patients receiving anthracyclines. Further investigation with larger randomized control trials and longer follow-up periods are needed to better evaluate the long-term role of statin therapy and identify the subgroups who benefit most from statin therapy.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1197-1204"},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sodium-Glucose Cotransporter 2 Inhibitors During Cancer Therapy: Benefits, Risks, and Ongoing Clinical Trials. 癌症治疗过程中的钠-葡萄糖转运体 2 抑制剂:收益、风险和正在进行的临床试验。
IF 4.7 2区 医学 Q1 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-07-11 DOI: 10.1007/s11912-024-01577-8
Nichanan Osataphan, Husam Abdel-Qadir, Agnieszka Maria Zebrowska, Anna Borowiec

Purpose of review: The goal of this paper is to summarize the data pertaining to the use of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) for the prevention of cardiotoxicity in patients receiving anthracyclines for cancer treatment. We discuss the potential efficacy of this class of medications, incorporating insights from existing literature and ongoing studies.

Recent findings: SGLT2i are a class of medications which were initially developed for treatment of Type 2 diabetes and later extended to treat heart failure with reduced and preserved ejection fraction regardless of diabetes status. There remains a need for effective and safe treatments to preventing cardiotoxicity in anthracycline-treated patients. It has been proposed that SGLT2i may provide protection against the cardiotoxic effects of anthracyclines. Some of the proposed mechanisms include beneficial metabolic, neurohormonal, and hemodynamic effects, renal protection, as well as a decrease in inflammation, oxidative stress, apoptosis, mitochondrial dysfunction and ion homeostasis. There is emerging evidence from basic science and observational studies that SGLT2i may play a role in the prevention of chemotherapy-induced cardiotoxicity. Randomized controlled trials are needed to conclusively determine the role of SGLT2 inhibitors as a cardioprotective therapy in patients receiving anthracyclines for the treatment of cancer.

综述目的:本文旨在总结钠-葡萄糖共转运体-2抑制剂(SGLT-2i)用于预防接受蒽环类药物治疗的癌症患者心脏毒性的相关数据。我们结合现有文献和正在进行的研究,讨论了这类药物的潜在疗效:SGLT2i 是一类最初用于治疗 2 型糖尿病的药物,后来扩展到治疗射血分数降低或保留的心力衰竭,与糖尿病状态无关。目前仍需要有效、安全的治疗方法来预防蒽环类药物治疗患者的心脏毒性。有人提出,SGLT2i 可为蒽环类药物的心脏毒性效应提供保护。提出的一些机制包括有益的代谢、神经激素和血液动力学效应、肾脏保护以及减少炎症、氧化应激、细胞凋亡、线粒体功能障碍和离子平衡。来自基础科学和观察性研究的新证据表明,SGLT2i 可在预防化疗引起的心脏毒性方面发挥作用。要最终确定 SGLT2 抑制剂在接受蒽环类药物治疗的癌症患者中作为心脏保护疗法的作用,还需要进行随机对照试验。
{"title":"Sodium-Glucose Cotransporter 2 Inhibitors During Cancer Therapy: Benefits, Risks, and Ongoing Clinical Trials.","authors":"Nichanan Osataphan, Husam Abdel-Qadir, Agnieszka Maria Zebrowska, Anna Borowiec","doi":"10.1007/s11912-024-01577-8","DOIUrl":"10.1007/s11912-024-01577-8","url":null,"abstract":"<p><strong>Purpose of review: </strong>The goal of this paper is to summarize the data pertaining to the use of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) for the prevention of cardiotoxicity in patients receiving anthracyclines for cancer treatment. We discuss the potential efficacy of this class of medications, incorporating insights from existing literature and ongoing studies.</p><p><strong>Recent findings: </strong>SGLT2i are a class of medications which were initially developed for treatment of Type 2 diabetes and later extended to treat heart failure with reduced and preserved ejection fraction regardless of diabetes status. There remains a need for effective and safe treatments to preventing cardiotoxicity in anthracycline-treated patients. It has been proposed that SGLT2i may provide protection against the cardiotoxic effects of anthracyclines. Some of the proposed mechanisms include beneficial metabolic, neurohormonal, and hemodynamic effects, renal protection, as well as a decrease in inflammation, oxidative stress, apoptosis, mitochondrial dysfunction and ion homeostasis. There is emerging evidence from basic science and observational studies that SGLT2i may play a role in the prevention of chemotherapy-induced cardiotoxicity. Randomized controlled trials are needed to conclusively determine the role of SGLT2 inhibitors as a cardioprotective therapy in patients receiving anthracyclines for the treatment of cancer.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1188-1196"},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing Care: Integrative Oncology in Myeloproliferative Neoplasm. 优化护理:骨髓增生性肿瘤的综合肿瘤学。
IF 4.7 2区 医学 Q1 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-07-05 DOI: 10.1007/s11912-024-01568-9
Shagun Singh, Supriya Peshin, Ashley Larsen, Krisstina Gowin

Purpose of review: Myeloproliferative neoplasm (MPN) burdens the lives of those affected. MPN patients endure significant impacts on their physical, psychological, and social well-being. While pharmacological interventions offer some disease and symptom control, they often have unfavorable side effects. This review explores the potential of Integrative Oncology (IO) therapies in managing MPNs and their associated symptoms.

Recent findings: IO is dedicated to augmenting conventional treatments through integrating interventions targeting the mind, body, nutrition, supplements, and other supportive care therapies. Several small studies suggest the benefit of an IO approach in MPN patients. These benefits are postulated to be modulated through enhanced physical capacity, reduced disease-related inflammation, subconscious mind training, and gut microbiome modulation. By combining IO with evidence-based pharmacological treatments, the potential exists to enhance the quality of life and clinical outcomes for individuals with MPNs. Future research should prioritize well-powered studies, including diverse demographics and symptom profiles, with appropriate study duration, to draw definite conclusions regarding the observed effects.

审查目的:骨髓增生性肿瘤(MPN)给患者的生活带来沉重负担。骨髓增生性肿瘤患者的身体、心理和社会福祉都受到严重影响。虽然药物干预能在一定程度上控制疾病和症状,但往往会产生不良副作用。本综述探讨了肿瘤综合疗法(IO)在控制 MPN 及其相关症状方面的潜力:中西医结合疗法致力于通过整合针对精神、身体、营养、补充剂和其他支持性护理疗法的干预措施来增强常规治疗。一些小型研究表明,IO疗法对多发性骨髓瘤患者有益。据推测,这些益处可通过增强体能、减少疾病相关炎症、潜意识思维训练和肠道微生物组调节来调节。通过将 IO 与循证药物治疗相结合,有可能提高 MPN 患者的生活质量和临床疗效。未来的研究应优先考虑动力充足的研究,包括不同的人口统计学和症状特征,以及适当的研究持续时间,以便就观察到的效果得出明确的结论。
{"title":"Optimizing Care: Integrative Oncology in Myeloproliferative Neoplasm.","authors":"Shagun Singh, Supriya Peshin, Ashley Larsen, Krisstina Gowin","doi":"10.1007/s11912-024-01568-9","DOIUrl":"10.1007/s11912-024-01568-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>Myeloproliferative neoplasm (MPN) burdens the lives of those affected. MPN patients endure significant impacts on their physical, psychological, and social well-being. While pharmacological interventions offer some disease and symptom control, they often have unfavorable side effects. This review explores the potential of Integrative Oncology (IO) therapies in managing MPNs and their associated symptoms.</p><p><strong>Recent findings: </strong>IO is dedicated to augmenting conventional treatments through integrating interventions targeting the mind, body, nutrition, supplements, and other supportive care therapies. Several small studies suggest the benefit of an IO approach in MPN patients. These benefits are postulated to be modulated through enhanced physical capacity, reduced disease-related inflammation, subconscious mind training, and gut microbiome modulation. By combining IO with evidence-based pharmacological treatments, the potential exists to enhance the quality of life and clinical outcomes for individuals with MPNs. Future research should prioritize well-powered studies, including diverse demographics and symptom profiles, with appropriate study duration, to draw definite conclusions regarding the observed effects.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1135-1145"},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Economics of Antibody Drug Conjugates (ADCs): Innovation, Investment and Market Dynamics. 抗体药物共轭物 (ADC) 的经济学:创新、投资和市场动态。
IF 4.7 2区 医学 Q1 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-07-22 DOI: 10.1007/s11912-024-01582-x
Arya Bhushan, Preeti Misra

Purpose of review: This review aims to explore the intricate interplay between scientific advancements and economic considerations in the development, production, and commercialization of Antibody Drug Conjugates (ADCs). The focus is on understanding the challenges and opportunities at this unique intersection, highlighting how scientific innovation and economic dynamics mutually influence the trajectory of ADCs in the pharmaceutical landscape.

Recent findings: There has been a significant increase in interest and investment in the development of ADCs. Initially focused on hematological malignancies, ADCs are now being researched for use in treating solid tumors as well. Pharmaceutical companies are heavily investing to broaden the range of indications for which ADCs can be effective. According to a report from the end of 2023, the global ADCs market grew from USD 1.4 billion in 2016 to USD 11.3 billion in 2023, with projections estimating a value of USD 23.9 billion by 2032, growing at a CAGR of 10.7%. ADCs represent a promising class of biopharmaceuticals in oncology, with expanding applications beyond hematological malignancies to solid tumors. The significant growth in the ADC market underscores the impact of scientific and economic factors on their development. This review provides valuable insights into how these factors drive innovation and commercialization, shaping the future of ADCs in cancer treatment.

综述的目的:本综述旨在探讨抗体药物共轭物 (ADC) 的开发、生产和商业化过程中科学进步与经济因素之间错综复杂的相互作用。重点是了解这一独特交叉点上的挑战和机遇,强调科学创新和经济动态如何相互影响 ADC 在制药领域的发展轨迹:对 ADC 开发的兴趣和投资大幅增加。ADC 最初主要用于治疗血液恶性肿瘤,现在也开始用于治疗实体瘤。制药公司正在大力投资,以扩大 ADC 的有效适应症范围。根据 2023 年底的一份报告,全球 ADCs 市场从 2016 年的 14 亿美元增长到 2023 年的 113 亿美元,预计到 2032 年将达到 239 亿美元,年复合增长率为 10.7%。ADC 是肿瘤领域一类前景广阔的生物制药,其应用已从血液恶性肿瘤扩展到实体瘤。ADC 市场的大幅增长凸显了科学和经济因素对其发展的影响。本综述就这些因素如何推动创新和商业化、塑造 ADC 在癌症治疗中的未来提供了宝贵的见解。
{"title":"Economics of Antibody Drug Conjugates (ADCs): Innovation, Investment and Market Dynamics.","authors":"Arya Bhushan, Preeti Misra","doi":"10.1007/s11912-024-01582-x","DOIUrl":"10.1007/s11912-024-01582-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review aims to explore the intricate interplay between scientific advancements and economic considerations in the development, production, and commercialization of Antibody Drug Conjugates (ADCs). The focus is on understanding the challenges and opportunities at this unique intersection, highlighting how scientific innovation and economic dynamics mutually influence the trajectory of ADCs in the pharmaceutical landscape.</p><p><strong>Recent findings: </strong>There has been a significant increase in interest and investment in the development of ADCs. Initially focused on hematological malignancies, ADCs are now being researched for use in treating solid tumors as well. Pharmaceutical companies are heavily investing to broaden the range of indications for which ADCs can be effective. According to a report from the end of 2023, the global ADCs market grew from USD 1.4 billion in 2016 to USD 11.3 billion in 2023, with projections estimating a value of USD 23.9 billion by 2032, growing at a CAGR of 10.7%. ADCs represent a promising class of biopharmaceuticals in oncology, with expanding applications beyond hematological malignancies to solid tumors. The significant growth in the ADC market underscores the impact of scientific and economic factors on their development. This review provides valuable insights into how these factors drive innovation and commercialization, shaping the future of ADCs in cancer treatment.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1224-1235"},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141733657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Geographical Disparities in Colorectal Cancer in Canada: A Review. 加拿大结直肠癌的地域差异:回顾。
IF 4.7 2区 医学 Q1 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-07-29 DOI: 10.1007/s11912-024-01574-x
Asal Rouhafzay, Jamileh Yousefi

Purpose of review: Colorectal cancer (CRC) is a prominent contributor to cancer-related mortality in Canada. This review paper sheds light on the research conducted in Canada to scrutinize the influence of economicfactors. The review seeks to uncover notable disparities in Colorectal cancer incidence and mortality rate across diverse Canadian populations, including Indigenous communities, rural dwellers, and individuals with lower socioeconomic status (SES).

Recent findings: Recent investigations reveal significant disparities in CRC incidence, mortality, and treatment outcomes among various demographic groups in Canada. Indigenous peoples, rural populations, and those with lower SES are particularly vulnerable to these disparities. Access to screening and specialized cancer care is notably limited for these marginalized populations, exacerbating existing health inequities. Furthermore, emerging evidence underscores the potential influence of dietary factors on CRC risk, highlighting the importance of tailored prevention and treatment strategies. The findings underscore the urgent need for targeted interventions aimed at enhancing access to CRC screening and specialized cancer care for disadvantaged populations in Canada. By addressing these disparities, more individuals can undergo timely screening and receive early-stage diagnoses, thereby improving prognosis and ultimately saving lives. However, to effectively bridge these gaps, further research is imperative to elucidate the underlying mechanisms driving these disparities and to identify and implement effective interventions.

审查目的:在加拿大,结直肠癌 (CRC) 是导致癌症相关死亡率的主要因素。这篇综述揭示了加拿大为仔细研究经济因素的影响而开展的研究。综述旨在揭示加拿大不同人群(包括土著社区、农村居民和社会经济地位(SES)较低的个人)在结直肠癌发病率和死亡率方面存在的明显差异:最近的调查显示,加拿大不同人口群体在结直肠癌发病率、死亡率和治疗效果方面存在显著差异。原住民、农村人口和社会经济地位较低的人群尤其容易受到这些差异的影响。这些边缘化人群获得筛查和专业癌症治疗的机会明显有限,加剧了现有的健康不平等。此外,新出现的证据强调了饮食因素对 CRC 风险的潜在影响,凸显了量身定制的预防和治疗策略的重要性。这些研究结果突出表明,加拿大迫切需要采取有针对性的干预措施,以提高弱势人群接受 CRC 筛查和专门癌症治疗的机会。通过解决这些差距,更多的人可以及时接受筛查和早期诊断,从而改善预后并最终挽救生命。然而,要有效弥补这些差距,必须开展进一步的研究,以阐明造成这些差异的根本机制,并确定和实施有效的干预措施。
{"title":"Geographical Disparities in Colorectal Cancer in Canada: A Review.","authors":"Asal Rouhafzay, Jamileh Yousefi","doi":"10.1007/s11912-024-01574-x","DOIUrl":"10.1007/s11912-024-01574-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>Colorectal cancer (CRC) is a prominent contributor to cancer-related mortality in Canada. This review paper sheds light on the research conducted in Canada to scrutinize the influence of economicfactors. The review seeks to uncover notable disparities in Colorectal cancer incidence and mortality rate across diverse Canadian populations, including Indigenous communities, rural dwellers, and individuals with lower socioeconomic status (SES).</p><p><strong>Recent findings: </strong>Recent investigations reveal significant disparities in CRC incidence, mortality, and treatment outcomes among various demographic groups in Canada. Indigenous peoples, rural populations, and those with lower SES are particularly vulnerable to these disparities. Access to screening and specialized cancer care is notably limited for these marginalized populations, exacerbating existing health inequities. Furthermore, emerging evidence underscores the potential influence of dietary factors on CRC risk, highlighting the importance of tailored prevention and treatment strategies. The findings underscore the urgent need for targeted interventions aimed at enhancing access to CRC screening and specialized cancer care for disadvantaged populations in Canada. By addressing these disparities, more individuals can undergo timely screening and receive early-stage diagnoses, thereby improving prognosis and ultimately saving lives. However, to effectively bridge these gaps, further research is imperative to elucidate the underlying mechanisms driving these disparities and to identify and implement effective interventions.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1249-1257"},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice? 微卫星稳定转移性结直肠癌的免疫疗法:我们能否缩小潜力与实践之间的差距?
IF 4.7 2区 医学 Q1 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-07-30 DOI: 10.1007/s11912-024-01583-w
Marwa Abdel Hamid, Lorenz M Pammer, Theresa K Lentner, Bernhard Doleschal, Rebecca Gruber, Florian Kocher, Elisabeth Gasser, Anna Jöbstl, Andreas Seeber, Arno Amann

Purpose of review: This review will explore various strategies to rendering MSS mCRCs susceptible to ICI. Moreover, we will provide an overview of potential biomarkers that may aid to better patient selection, and discuss ongoing efforts in this area of research.

Recent findings: Colorectal cancer (CRC) ranks among the top three most common cancers worldwide. While significant advances in treatment strategies have improved the prognosis for patients in the early stages of the disease, treatment options for metastatic CRC (mCRC) remain limited. Although immune checkpoint inhibitors (ICI) have revolutionized the treatment of several malignancies, its efficacy in mCRC is largely confined to patients exhibiting a high microsatellite instability status (MSI-H). However, the vast majority of mCRC patients do not exhibit a MSI-H, but are microsatellite stable (MSS). In these patients ICIs are largely ineffective. So far, ICIs do not play a crucial role in patients with MSS mCRC, despite the promising data for inducing long-term remissions in other tumour entities. For this reason, novel treatment strategies are needed to overcome the primary resistance upon ICI in patients with MSS.

综述的目的:本综述将探讨使 MSS mCRC 易受 ICI 影响的各种策略。此外,我们还将概述有助于更好地选择患者的潜在生物标志物,并讨论这一研究领域正在进行的工作:结直肠癌(CRC)是全球三大常见癌症之一。虽然治疗策略的重大进展改善了疾病早期患者的预后,但转移性结直肠癌(mCRC)的治疗方案仍然有限。尽管免疫检查点抑制剂(ICI)已经彻底改变了多种恶性肿瘤的治疗方法,但其对 mCRC 的疗效主要局限于微卫星不稳定性较高(MSI-H)的患者。然而,绝大多数 mCRC 患者并不表现出 MSI-H,而是微卫星稳定(MSS)。对这些患者来说,ICIs 基本上是无效的。迄今为止,尽管在其他肿瘤实体中诱导长期缓解的数据很有希望,但 ICIs 在 MSS mCRC 患者中并没有发挥关键作用。因此,需要新的治疗策略来克服 MSS 患者对 ICI 的原发性耐药性。
{"title":"Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?","authors":"Marwa Abdel Hamid, Lorenz M Pammer, Theresa K Lentner, Bernhard Doleschal, Rebecca Gruber, Florian Kocher, Elisabeth Gasser, Anna Jöbstl, Andreas Seeber, Arno Amann","doi":"10.1007/s11912-024-01583-w","DOIUrl":"10.1007/s11912-024-01583-w","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review will explore various strategies to rendering MSS mCRCs susceptible to ICI. Moreover, we will provide an overview of potential biomarkers that may aid to better patient selection, and discuss ongoing efforts in this area of research.</p><p><strong>Recent findings: </strong>Colorectal cancer (CRC) ranks among the top three most common cancers worldwide. While significant advances in treatment strategies have improved the prognosis for patients in the early stages of the disease, treatment options for metastatic CRC (mCRC) remain limited. Although immune checkpoint inhibitors (ICI) have revolutionized the treatment of several malignancies, its efficacy in mCRC is largely confined to patients exhibiting a high microsatellite instability status (MSI-H). However, the vast majority of mCRC patients do not exhibit a MSI-H, but are microsatellite stable (MSS). In these patients ICIs are largely ineffective. So far, ICIs do not play a crucial role in patients with MSS mCRC, despite the promising data for inducing long-term remissions in other tumour entities. For this reason, novel treatment strategies are needed to overcome the primary resistance upon ICI in patients with MSS.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1258-1270"},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perioperative NETosis and Cancer Progression: Current Evidence and Future Perspectives. 围手术期 NETosis 与癌症进展:当前证据与未来展望》。
IF 4.7 2区 医学 Q1 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-07-16 DOI: 10.1007/s11912-024-01573-y
Qiang Zhang, Jing Zhang, Haiyun Gu, Yan Yang, Hao Zhang, Changhong Miao

Purpose of review: The process of neutrophil extracellular traps (NETs) formation, called NETosis, is a peculiar death modality of neutrophils, which was first observed as an immune response against bacterial infection. However, an ongoing and exaggerated NETs formation may have adverse clinical consequences and even promote cancer progression. This review will discuss the complex relationship between NETosis and cancer progression.

Recent findings: NETs exhibits cancer-promoting effects by causing cancer metastaisis and tumor-associated thrombosis. Many studies have found that many mechanisms are involved in the process, and the corresponding targets could be applied for cancer therapy. Although NETs may have anti-bacteria effects, it is necessary to inhibit an excessive NETs formation, mostly showing cancer-promoting effects. The contribution of NETs to cancer progression has gained a growing appreciation and the approaches to targeting NETs deposition exhibited beneficial effects both in primary and metastatic tumors, which, however, has been challenged by a recent finding demonstrating an opposite effect of NETs to suppress tumor growth via the activation of immune response against tumor. This seeming discrepancy reflects we are in the early stage of NETs study facing fundamental questions and a better understanding of the underlying mechanism is urgently needed.

综述的目的:中性粒细胞胞外捕获物(NETs)的形成过程被称为 "NETosis",是中性粒细胞的一种特殊死亡方式,最早是作为一种抵抗细菌感染的免疫反应被观察到的。然而,持续而夸张的中性粒细胞胞外捕获物(NETs)形成可能会产生不良的临床后果,甚至会促进癌症进展。本综述将讨论 NETosis 与癌症进展之间的复杂关系:最近的研究发现:NETs 通过引起癌症转移和肿瘤相关血栓形成而表现出促癌作用。许多研究发现,这一过程涉及多种机制,相应的靶点可用于癌症治疗。虽然 NETs 具有抗菌作用,但有必要抑制过量 NETs 的形成,因为过量的 NETs 大多具有促癌作用。人们越来越认识到 NETs 对癌症进展的作用,针对 NETs 沉积的方法对原发性和转移性肿瘤都有益处,但最近的一项研究发现,NETs 通过激活针对肿瘤的免疫反应来抑制肿瘤生长,从而起到相反的作用。这种看似矛盾的现象反映出我们对 NETs 的研究还处于早期阶段,面临着一些基本问题,迫切需要更好地了解其潜在机制。
{"title":"Perioperative NETosis and Cancer Progression: Current Evidence and Future Perspectives.","authors":"Qiang Zhang, Jing Zhang, Haiyun Gu, Yan Yang, Hao Zhang, Changhong Miao","doi":"10.1007/s11912-024-01573-y","DOIUrl":"10.1007/s11912-024-01573-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>The process of neutrophil extracellular traps (NETs) formation, called NETosis, is a peculiar death modality of neutrophils, which was first observed as an immune response against bacterial infection. However, an ongoing and exaggerated NETs formation may have adverse clinical consequences and even promote cancer progression. This review will discuss the complex relationship between NETosis and cancer progression.</p><p><strong>Recent findings: </strong>NETs exhibits cancer-promoting effects by causing cancer metastaisis and tumor-associated thrombosis. Many studies have found that many mechanisms are involved in the process, and the corresponding targets could be applied for cancer therapy. Although NETs may have anti-bacteria effects, it is necessary to inhibit an excessive NETs formation, mostly showing cancer-promoting effects. The contribution of NETs to cancer progression has gained a growing appreciation and the approaches to targeting NETs deposition exhibited beneficial effects both in primary and metastatic tumors, which, however, has been challenged by a recent finding demonstrating an opposite effect of NETs to suppress tumor growth via the activation of immune response against tumor. This seeming discrepancy reflects we are in the early stage of NETs study facing fundamental questions and a better understanding of the underlying mechanism is urgently needed.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1169-1175"},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiogenomics as an Integrated Approach to Glioblastoma Precision Medicine. 放射基因组学是胶质母细胞瘤精准医疗的综合方法。
IF 4.7 2区 医学 Q1 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-07-16 DOI: 10.1007/s11912-024-01580-z
Isabella Sanchez, Ruman Rahman

Purpose of review: Isocitrate dehydrogenase wild-type glioblastoma is the most aggressive primary brain tumour in adults. Its infiltrative nature and heterogeneity confer a dismal prognosis, despite multimodal treatment. Precision medicine is increasingly advocated to improve survival rates in glioblastoma management; however, conventional neuroimaging techniques are insufficient in providing the detail required for accurate diagnosis of this complex condition.

Recent findings: Advanced magnetic resonance imaging allows more comprehensive understanding of the tumour microenvironment. Combining diffusion and perfusion magnetic resonance imaging to create a multiparametric scan enhances diagnostic power and can overcome the unreliability of tumour characterisation by standard imaging. Recent progress in deep learning algorithms establishes their remarkable ability in image-recognition tasks. Integrating these with multiparametric scans could transform the diagnosis and monitoring of patients by ensuring that the entire tumour is captured. As a corollary, radiomics has emerged as a powerful approach to offer insights into diagnosis, prognosis, treatment, and tumour response through extraction of information from radiological scans, and transformation of these tumour characteristics into quantitative data. Radiogenomics, which links imaging features with genomic profiles, has exhibited its ability in characterising glioblastoma, and determining therapeutic response, with the potential to revolutionise management of glioblastoma. The integration of deep learning algorithms into radiogenomic models has established an automated, highly reproducible means to predict glioblastoma molecular signatures, further aiding prognosis and targeted therapy. However, challenges including lack of large cohorts, absence of standardised guidelines and the 'black-box' nature of deep learning algorithms, must first be overcome before this workflow can be applied in clinical practice.

综述目的:异柠檬酸脱氢酶野生型胶质母细胞瘤是成人中最具侵袭性的原发性脑肿瘤。尽管接受了多模式治疗,但其浸润性和异质性使其预后不容乐观。为了提高胶质母细胞瘤治疗的存活率,越来越多的人提倡精准医疗;然而,传统的神经成像技术不足以提供准确诊断这种复杂疾病所需的细节:最新研究结果:先进的磁共振成像技术可以更全面地了解肿瘤微环境。将弥散和灌注磁共振成像技术相结合,形成多参数扫描,可提高诊断能力,并克服标准成像对肿瘤特征描述不可靠的问题。深度学习算法的最新进展证明了其在图像识别任务中的卓越能力。将这些算法与多参数扫描相结合,可确保捕捉到整个肿瘤,从而改变对患者的诊断和监测。作为必然结果,放射组学已成为一种强大的方法,通过从放射扫描中提取信息,并将这些肿瘤特征转化为定量数据,为诊断、预后、治疗和肿瘤反应提供见解。放射基因组学将成像特征与基因组图谱联系起来,在描述胶质母细胞瘤的特征和确定治疗反应方面显示出其能力,有望彻底改变胶质母细胞瘤的管理。将深度学习算法整合到放射基因组学模型中,建立了一种预测胶质母细胞瘤分子特征的自动化、可重复性高的方法,可进一步帮助预后判断和靶向治疗。然而,在将这一工作流程应用于临床实践之前,必须首先克服各种挑战,包括缺乏大型队列、缺乏标准化指南以及深度学习算法的 "黑箱 "性质。
{"title":"Radiogenomics as an Integrated Approach to Glioblastoma Precision Medicine.","authors":"Isabella Sanchez, Ruman Rahman","doi":"10.1007/s11912-024-01580-z","DOIUrl":"10.1007/s11912-024-01580-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>Isocitrate dehydrogenase wild-type glioblastoma is the most aggressive primary brain tumour in adults. Its infiltrative nature and heterogeneity confer a dismal prognosis, despite multimodal treatment. Precision medicine is increasingly advocated to improve survival rates in glioblastoma management; however, conventional neuroimaging techniques are insufficient in providing the detail required for accurate diagnosis of this complex condition.</p><p><strong>Recent findings: </strong>Advanced magnetic resonance imaging allows more comprehensive understanding of the tumour microenvironment. Combining diffusion and perfusion magnetic resonance imaging to create a multiparametric scan enhances diagnostic power and can overcome the unreliability of tumour characterisation by standard imaging. Recent progress in deep learning algorithms establishes their remarkable ability in image-recognition tasks. Integrating these with multiparametric scans could transform the diagnosis and monitoring of patients by ensuring that the entire tumour is captured. As a corollary, radiomics has emerged as a powerful approach to offer insights into diagnosis, prognosis, treatment, and tumour response through extraction of information from radiological scans, and transformation of these tumour characteristics into quantitative data. Radiogenomics, which links imaging features with genomic profiles, has exhibited its ability in characterising glioblastoma, and determining therapeutic response, with the potential to revolutionise management of glioblastoma. The integration of deep learning algorithms into radiogenomic models has established an automated, highly reproducible means to predict glioblastoma molecular signatures, further aiding prognosis and targeted therapy. However, challenges including lack of large cohorts, absence of standardised guidelines and the 'black-box' nature of deep learning algorithms, must first be overcome before this workflow can be applied in clinical practice.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1213-1222"},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Past, Present, and Future Therapeutic Strategies for NF‑1‑Associated Tumors. 更正:NF-1相关肿瘤过去、现在和未来的治疗策略。
IF 4.7 2区 医学 Q1 ONCOLOGY Pub Date : 2024-10-01 DOI: 10.1007/s11912-024-01581-y
Brian Na, Shilp R Shah, Harish N Vasudevan
{"title":"Correction to: Past, Present, and Future Therapeutic Strategies for NF‑1‑Associated Tumors.","authors":"Brian Na, Shilp R Shah, Harish N Vasudevan","doi":"10.1007/s11912-024-01581-y","DOIUrl":"10.1007/s11912-024-01581-y","url":null,"abstract":"","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1223"},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141723275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarkers in the Immuno-oncology Interface of Triple Negative Breast Cancer: A Scoping Review with Perioperative Considerations. 三阴性乳腺癌免疫肿瘤学界面的生物标记物:围手术期考虑因素范围综述》。
IF 4.7 2区 医学 Q1 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-07-06 DOI: 10.1007/s11912-024-01572-z
Laura Smith, John Saganty, Patrice Forget

Purpose of review: Identification of biomarkers for immunotherapy treatment in triple negative breast cancer remains crucial for improving outcomes and optimising regimes, particularly in the perioperative setting. There is a need to conduct a scoping review to provide an overview of current research, explore the wider context, and highlight future research considerations in this field.

Recent findings: The most commonly assessed biomarkers are PD-L1, TILs and CD8 + cells with correlation to outcomes mainly focused on survival. There is a growing interest in evaluating genetic markers. Conclusions are currently limited by knowledge gaps around contextual factors. Important areas of focus for future research include a greater understanding of complex cellular, genetic and metabolic interactions in the perioperative tumour microenvironment, including patient-specific immune profiles. An important challenge remains elucidating the clinical significance of the immunological effects of interventions at each stage of the perioperative period, including the use of anaesthetic agents.

综述的目的:鉴定三阴性乳腺癌免疫疗法治疗的生物标志物对于改善疗效和优化治疗方案仍然至关重要,尤其是在围手术期。有必要进行一次范围界定综述,以概述当前的研究,探索更广泛的背景,并强调该领域未来研究的注意事项:最常评估的生物标志物是 PD-L1、TILs 和 CD8 + 细胞,与预后的相关性主要集中在存活率上。人们对评估遗传标记物的兴趣日益浓厚。目前,由于对背景因素的认识不足,得出的结论还很有限。未来研究的重点领域包括进一步了解围手术期肿瘤微环境中复杂的细胞、基因和代谢相互作用,包括患者特异性免疫特征。阐明围手术期各阶段干预措施(包括使用麻醉剂)对免疫学影响的临床意义仍是一项重要挑战。
{"title":"Biomarkers in the Immuno-oncology Interface of Triple Negative Breast Cancer: A Scoping Review with Perioperative Considerations.","authors":"Laura Smith, John Saganty, Patrice Forget","doi":"10.1007/s11912-024-01572-z","DOIUrl":"10.1007/s11912-024-01572-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>Identification of biomarkers for immunotherapy treatment in triple negative breast cancer remains crucial for improving outcomes and optimising regimes, particularly in the perioperative setting. There is a need to conduct a scoping review to provide an overview of current research, explore the wider context, and highlight future research considerations in this field.</p><p><strong>Recent findings: </strong>The most commonly assessed biomarkers are PD-L1, TILs and CD8 + cells with correlation to outcomes mainly focused on survival. There is a growing interest in evaluating genetic markers. Conclusions are currently limited by knowledge gaps around contextual factors. Important areas of focus for future research include a greater understanding of complex cellular, genetic and metabolic interactions in the perioperative tumour microenvironment, including patient-specific immune profiles. An important challenge remains elucidating the clinical significance of the immunological effects of interventions at each stage of the perioperative period, including the use of anaesthetic agents.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1159-1168"},"PeriodicalIF":4.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141544686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Oncology Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1